Active‑placebo cocktails for psychedelic trials

Psychedelic trials should use multi‑drug active placebos plus limited disclosure to better preserve blinding. The approach aims to replicate some perceptual and somatic cues of psychedelics without therapeutic action, reducing participants' ability to infer treatment and lowering expectancy bias in outcome measures. — If adopted, this methodological shift would change how evidence for psychedelic medicines is generated, potentially altering FDA approvals, prescribing norms, and public confidence in those therapies.